These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34622186)

  • 1. Effectiveness and cost-effectiveness of RSV infant and maternal immunization programs: A case study of Nunavik, Canada.
    Nourbakhsh S; Shoukat A; Zhang K; Poliquin G; Halperin D; Sheffield H; Halperin SA; Langley JM; Moghadas SM
    EClinicalMedicine; 2021 Nov; 41():101141. PubMed ID: 34622186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan.
    Ishiwada N; Akaishi R; Kobayashi Y; Togo K; Yonemoto N; Matsuo M; Kaneko S; Law AW; Kamei K
    Infect Dis Ther; 2024 Jul; 13(7):1665-1682. PubMed ID: 38834858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic.
    Tam DY; Banerji A; Paes BA; Hui C; Tarride JE; Lanctôt KL
    J Med Econ; 2009; 12(4):361-70. PubMed ID: 19900071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
    Nuijten MJ; Wittenberg W; Lebmeier M
    Pharmacoeconomics; 2007; 25(1):55-71. PubMed ID: 17192118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.
    Shoukat A; Abdollahi E; Galvani AP; Halperin SA; Langley JM; Moghadas SM
    Lancet Reg Health Am; 2023 Dec; 28():100629. PubMed ID: 38026446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.
    McGirr AA; Schwartz KL; Allen U; Solomon M; Sander B
    Hum Vaccin Immunother; 2017 Mar; 13(3):599-606. PubMed ID: 27768505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Shoukat A; Bawden CE; Röst G; LeBlanc JJ; Galvani AP; Langley JM; Moghadas SM
    Vaccine; 2024 Mar; 42(7):1768-1776. PubMed ID: 38368226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
    Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S
    Front Immunol; 2022; 13():880368. PubMed ID: 35572550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review.
    Prescott WA; Doloresco F; Brown J; Paladino JA
    Pharmacoeconomics; 2010; 28(4):279-93. PubMed ID: 20131925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.
    Blanken MO; Frederix GW; Nibbelke EE; Koffijberg H; Sanders EAM; Rovers MM; Bont L;
    Eur J Pediatr; 2018 Jan; 177(1):133-144. PubMed ID: 29168012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
    BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
    Rodgers-Gray BS; Fullarton JR; Carbonell-Estrany X; Keary IP; Tarride JÉ; Paes BA
    J Med Econ; 2023; 26(1):630-643. PubMed ID: 37067826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of palivizumab compared to no prophylaxis in term infants residing in the Canadian Arctic.
    Banerji A; Ng K; Moraes TJ; Panzov V; Robinson J; Lee BE
    CMAJ Open; 2016; 4(4):E623-E633. PubMed ID: 28443266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
    Keary IP; Ravasio R; Fullarton JR; Manzoni P; Lanari M; Paes BA; Carbonell-Estrany X; Baraldi E; Tarride JÉ; Rodgers-Gray B
    PLoS One; 2023; 18(8):e0289828. PubMed ID: 37561741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.